Redeye: Orexo - Prescription Data and Estimates Update

Redeye believes that Orexo will have a better Q1 than previously expected, mainly due to patients and wholesalers building up inventory, somewhat lower costs and a stronger USD against the SEK.

Read more and download the Research Update: https://bit.ly/3aT2pWl

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/